[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Epiomic Epidemiology Series: Leukaemia Forecast in 18 Major Markets 2017-2027

December 2016 | 82 pages | ID: EF035B66787EN
Black Swan Analysis limited

US$ 6,150.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Multiple Sclerosis (MS) (also known as disseminated sclerosis) is a chronic, inflammatory demyelinating immune-mediated disease of the central nervous system (CNS). MS is characterised by the formation of lesions in the central nervous system, the destruction of the myelin sheath (insulation surrounding the nerve fibres of the CNS) and inflammation. Patients can exhibit a broad range of signs and symptoms associated with neural damage and dysfunction.

This report provides the current prevalent population for Multiple Sclerosis across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Turkey, Australia, Poland, Romania, Russia, Mexico, Argentina, Brazil, Japan, India, China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Multiple Sclerosis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Multiple Sclerosis include:
  • Osteoporosis
  • Osteopenia
  • Diabetes
  • Hyperlipidaemia
  • Hypertension
  • Uveitis
  • Muscle stiffness or spasms
  • Paralysis (typically of the legs)
  • Problems with the bladder/bowel/sexual function
  • Mental changes (forgetfulness/mood swings)
  • Depression
  • Epilepsy
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Multiple Sclerosis market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Multiple Sclerosis and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Multiple Sclerosis prevalent population.
  • Identify sub-populations within Multiple Sclerosis which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Multiple Sclerosis patients.
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key comorbid features associated with the disease
Methodology for quantification of patient numbers
Top-line Incidence for Leukaemia
Type of Leukaemia
Lymphocytic Leukaemia
  Acute Lymphocytic Leukaemia
  Chronic Lymphocytic Leukaemia
Myeloid & Monocytic Leukaemia
  Chronic Myeloid Leukaemia
Other Types of Leukaemia
Treatment Rates
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

LIST OF TABLES

The Rai staging system for CLL
CML Prognostic scores
Incidence of leukaemia, total (000s)
Incidence of leukaemia, males (000s)
Incidence of leukaemia, females (000s)
Type of Leukaemia, total (000s)
Type of Lymphocytic Leukaemia, total (000s)
Subtype of Acute lymphocytic Leukaemia, total (000s)
Philadelphia chromosome abnormality in ALL patients, total (000s)
CLL patients by Rai Stage, total (000s)
CLL patients with 17p Deletion, total (000s)
CLL patients with Haemolytic anaemia, total (000s)
Type of Myeloid/ Monocytic Leukaemia, total (000s)
Type of CML, total (000s)
Phase at Diagnosis of CML patients, total (000s)
CML patients by Sokal Risk Score, total (000s)
CML patients by Hasford Risk Score, total (000s)
Spleen size, total (000s)
Other Leukaemias, total (000s)
CLL treated patients by line of therapy, total (000s)
CML treated patients by line of therapy, total (000s)
Abbreviations and Acronyms used in the report
USA Incidence of Leukaemia by 5-yr age cohort, males (000s)
USA Incidence of Leukaemia by 5-yr age cohort, females (000s)
Canada Incidence of Leukaemia by 5-yr age cohort, males (000s)
Canada Incidence of Leukaemia by 5-yr age cohort, females (000s)
France Incidence of Leukaemia by 5-yr age cohort, males (000s)
France Incidence of Leukaemia by 5-yr age cohort, females (000s)
Germany Incidence of Leukaemia by 5-yr age cohort, males (000s)
Germany Incidence of Leukaemia by 5-yr age cohort, females (000s)
Italy Incidence of Leukaemia by 5-yr age cohort, males (000s)
Italy Incidence of Leukaemia by 5-yr age cohort, females (000s)
Spain Incidence of Leukaemia by 5-yr age cohort, males (000s)
Spain Incidence of Leukaemia by 5-yr age cohort, females (000s)
UK Incidence of Leukaemia by 5-yr age cohort, males (000s)
UK Incidence of Leukaemia by 5-yr age cohort, females (000s)
Brazil Incidence of Leukaemia by 5-yr age cohort, males (000s)
Brazil Incidence of Leukaemia by 5-yr age cohort, females (000s)
Japan Incidence of Leukaemia by 5-yr age cohort, males (000s)
Japan Incidence of Leukaemia by 5-yr age cohort, females (000s)
India Incidence of Leukaemia by 5-yr age cohort, males (000s)
India Incidence of Leukaemia by 5-yr age cohort, females (000s)
China Incidence of Leukaemia by 5-yr age cohort, males (000s)
China Incidence of Leukaemia by 5-yr age cohort, females (000s)
Turkey Incidence of Leukaemia by 5-yr age cohort, males (000s)
Turkey Incidence of Leukaemia by 5-yr age cohort, females (000s)
Australia Incidence of Leukaemia by 5-yr age cohort, males (000s)
Australia Incidence of Leukaemia by 5-yr age cohort, females (000s)
Mexico Incidence of Leukaemia by 5-yr age cohort, males (000s)
Mexico Incidence of Leukaemia by 5-yr age cohort, females (000s)
Argentina Incidence of Leukaemia by 5-yr age cohort, males (000s)
Argentina Incidence of Leukaemia by 5-yr age cohort, females (000s)
Russia Incidence of Leukaemia by 5-yr age cohort, males (000s)
Russia Incidence of Leukaemia by 5-yr age cohort, females (000s)
Saudi Arabia Incidence of Leukaemia by 5-yr age cohort, males (000s)
Saudi Arabia Incidence of Leukaemia by 5-yr age cohort, females (000s)
South Africa Incidence of Leukaemia by 5-yr age cohort, males (000s)
South Africa Incidence of Leukaemia by 5-yr age cohort, females (000s)


More Publications